Carlsmed (CARL) Truist Securities MedTech Conference 2026 summary
Event summary combining transcript, slides, and related documents.
Truist Securities MedTech Conference 2026 summary
17 Jun, 2026Business model and technology platform
Focuses on personalized surgery using patient and surgeon data to create 3D models and 3D-printed devices, enabling better outcomes and lower healthcare costs.
Operates as a digital-first, software-driven company with a closed-loop system that collects and uses post-op data to continuously improve algorithms and outcomes.
No inventory is required due to on-demand 3D printing and direct delivery to operating rooms, supporting rapid scalability.
Initially targeted complex adult spinal deformity, expanding to degenerative disc disease and cervical indications.
Utilizes big data and AI to refine surgical planning and device creation, creating a flywheel effect as more procedures are performed.
Market adoption and growth
Installed base grew 60% year-over-year in Q1, with strong adoption among early and mid-career surgeons, especially through teaching institutions.
Surgeons trained in residency are bringing the procedure to private practice and new academic centers, accelerating adoption.
Cervical platform launched in December, with 20% of total surgeons trained on it within a short period.
Corra platform, targeting cervical plating, had first procedures in February and is set for full commercial launch in December.
Expectation for significant pull-through from lumbar to cervical procedures, with investments in medical education to support this.
Reimbursement and regulatory environment
CMS is proposing to consolidate lumbar cases into three DRGs, simplifying reimbursement and potentially accelerating hospital adoption.
Medicare’s changes are expected to provide broader access and economic benefits for hospitals and payers, with the final rule effective October 1.
Anticipates the new DRG structure will materially benefit adoption and utilization from 2027 onward.
Latest events from Carlsmed
- Personalized AI spine surgery platform accelerates growth with new reimbursement and strong clinical data.CARL
Bank of America SMID Cap Virtual Conference - Q2 revenue up 57% YoY to $18.9M; guidance raised on strong demand and CMS reimbursement changes.CARL
Q2 2026 - Personalized spine surgery tech sees rapid adoption, strong outcomes, and margin expansion.CARL
Bank of America Global Healthcare Conference 2026 - Personalized AI-enabled spine surgery platform drives growth, clinical impact, and premium reimbursement.CARL
Corporate presentation - Q1 2026 revenue up 58% to $16.1M, gross margin 77.1%, and guidance raised to $72–77M.CARL
Q1 2026 - Vote on director elections and auditor ratification at the June 2026 annual meeting.CARL
Proxy filing - Proxy covers director elections, auditor ratification, governance, compensation, and ESG oversight.CARL
Proxy filing - AI-driven personalized spine surgery platform drives strong growth and clinical outcomes.CARL
25th Annual Needham Virtual Healthcare Conference - 2025 revenue surged 86% with robust margins and new launches; 2026 outlook remains strong.CARL
Q4 2025